Checks out so far.

“In a 711-participant randomized phase 2b trial of heart failure with preserved or mildly reduced ejection fraction, 48 weeks of mitiperstat did not improve symptoms, six-minute walk distance, or secondary endpoints versus placebo, although safety was generally similar.”

3 of 4 review checks done · 1 counted · 2 by the author only

Supported · 0.9908 under ledger-default@0.3.0 at snapshot 27745 · review checks 1 of 4 · provisional until audited. The number is model-conditional, not a share of truth.